DiaMedica Therapeutics Inc. (DMAC): Price and Financial Metrics


DiaMedica Therapeutics Inc. (DMAC): $1.30

-0.72 (-35.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DMAC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DMAC Stock Price Chart Interactive Chart >

Price chart for DMAC

DMAC Price/Volume Stats

Current price $1.30 52-week high $4.82
Prev. close $2.02 52-week low $1.15
Day low $1.15 Volume 2,393,572
Day high $1.31 Avg. volume 79,161
50-day MA $2.30 Dividend yield N/A
200-day MA $3.06 Market Cap 34.38M

DiaMedica Therapeutics Inc. (DMAC) Company Bio


DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.


DMAC Latest News Stream


Event/Time News Detail
Loading, please wait...

DMAC Latest Social Stream


Loading social stream, please wait...

View Full DMAC Social Stream

Latest DMAC News From Around the Web

Below are the latest news stories about DiaMedica Therapeutics Inc that investors may wish to consider to help them evaluate DMAC as an investment opportunity.

Maxim Group Thinks Diamedica Therapeutics’ Stock is Going to Recover

In a report issued on February 2, Jason McCarthy from Maxim Group maintained a Buy rating on Diamedica Therapeutics (DMAC – Research Report), with a price target of $6.00. The company's shares closed last Friday at $2.77, close to its 52-week low of $2.20. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

Catie Powers on TipRanks | February 6, 2022

DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | February 4, 2022

DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer

MINNEAPOLIS, February 02, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Dominic Cundari as Chief Commercial Officer. In this role, Mr. Cundari will be focused primarily on the commercial planning, positioning and launch preparations for DM199 in acute ischemic stroke.

Yahoo | February 2, 2022

DiaMedica Therapeutics to Present Research at International Stroke Conference

MINNEAPOLIS, January 25, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 – 11, 2022. For information about the event, visit: https://professional.heart.org/en/meetings/int

Yahoo | January 25, 2022

DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

MINNEAPOLIS, January 05, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Kirsten Gruis, M.D. as Chief Medical Officer. Dr. Gruis is a board-certified neurologist with 20 years of experience in both clinical medicine and drug development in large and small biopharmaceutical companies.

Yahoo | January 5, 2022

Read More 'DMAC' Stories Here

DMAC Price Returns

1-mo -45.61%
3-mo -42.48%
6-mo -63.79%
1-year -69.12%
3-year -73.14%
5-year N/A
YTD -65.15%
2021 -63.21%
2020 109.07%
2019 66.67%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4798 seconds.